Tagged with Italy,

Italy Italy, Europe’s fourth largest pharma market at a size of EUR 23.446 billion, has a highly decentralised healthcare system, with the country’s 20 regions negotiating market access for medicines individually following central regulatory approval. This creates significant complexities for the representatives of Big Pharma looking to roll out their latest…

Spain Kyowa Kirin’s head of the South Europe cluster, Norberto Villarrasa, explains the Japanese company’s presence in Spain, its focus on rare diseases and onco-haematology, and comments on the challenges around access to rare disease treatments. In addition, the executive provides the company’s view on the potential and advantages of risk-sharing…

Italy Pierre Fabre Italy’s Charles-Henri Bodin highlights how the French firm’s offering has expanded far beyond its dermo-cosmetics heritage to today encompass a wide range of pharmaceuticals, including the key growth area of oncology. Bodin also outlines the importance of Italy – one of PF’s first international affiliates – to the…

Italy Domenico Mantoan, General Manager of AGENAS, the Italian National Agency for Regional Health Services, discusses the role of the agency in Italy’s decentralised healthcare system, the National Recovery and Resilience Plan’s aim to improve territorial inequalities, and the National Outcomes Program managed by AGENAS on behalf of the Ministry of…

Italy Nicoletta Luppi, MSD Italia’s Senior Vice President & Managing Director details the need for healthcare reform in Italy and walks us through MSD’s portfolio priorities. In addition, she explains the Italian affiliate’s Equity and Inclusion initiatives.  Since the Organon spinoff, the strategy to focus on specific parts of the portfolio…

Italy In recent years, since the adoption of a law assuring its citizens’ right to access palliative care, Italy has given increased attention to pain management. According to Aldo Sterpone, Italy General Manager at Grünenthal, a company especially focused on the area of pain, there is still a lot of work…

Italy Aldo Sterpone, Grünenthal Italia’s General Manager, outlines the company’s focus on pain and its efforts to bring innovation to the area through R&D and acquisitions. He also explains the importance of Italy as one of Grünenthal’s manufacturing hubs. We are one of the few companies focusing heavily on pain. There…

Italy We spoke with Luca Crippa, CEO and Managing Director at IBSA Farmaceutici, about the company’s approach to developing new delivery technologies for existing and natural molecules, its focus on endocrinology, fertility, orthopaedics and aesthetic medicine, and the group’s new affiliates in the US, France, Germany and the UK. … the…

Italy Stevanato Group’s CEO & COO, Franco Moro explaines how the over 70-year-old provider of  containment and delivery solutions went public and as an established player in the vaccine space managed to service large pharmaceutical companies during the pandemic. He also speaks about the company’s move towards further internationalisation. … the…

Italy CAI is an engineering service company. Its regional manager for South Europe, Andrea Castiglioni, comments on the pharma industry’s need for commissioning and qualification services when looking to reduce time to market or set up new production facilities. He also outlines the role of CAI in helping companies who produce…

Italy Merck Italia’s Managing Director & President, Jan Kirsten explains the importance of the Italian affiliate within the global organisation, Merck’s aim to strengthen its position in oncology and the challenges of fertility in a country with one of the lowest birthrates in the world. [In Italy] we have the full…

Italy Over the past decade, the birth rate in Italy has consistently decreased, making it one of the countries with the lowest birth rates in the world but also one of the top reproductive medicine markets in Europe. According to Italy’s national statistics office, births in Italy between 2020-2021 hit their…